Young Black women experience breast cancer at higher rates than their White peers. Here's how you can find out your risks. Lower education levels, lower income, unemployment, and having more than 1 child were associated with more decision conflict. Survey respondents felt especially displeased when their social circle offered “reassuring” comments. Although recollection may be skewed, many patients reported not being told cancer could recur. In a qualitative survey, 4 themes emerged that captured the general sentiments of respondents. This study showed that remote symptom-report monitoring generally results in on-time responses from oncology nurses. Does the route of administration for HER2 targeted therapy affect overall and progression-free survival? Certain intrinsic molecular subtypes changed after metastasis compared to the primary tumor subtype. Overall survival was the least favorable when brain metastasis was diagnosed during or after second-line treatment. According to a novel prognostic model, patients classified as low-risk had better overall survival. Patients with HR+/HER2- early-stage breast cancer classified as H2 were more likely to respond to chemotherapy. Even with a recurrence score <11, patients who were staged higher had worse overall survival. Some organizations recommend annual breast cancer screenings for women over 40, but what is the lifetime cost? Rural residents had lower breast cancer-specific survival and a higher risk of relapse, though the reasoning is unclear. Patients with the UGT1A1 *28/*28 genotype were more likely to experience toxicity leading to discontinuation of SG. Multivariable analysis showed no factors associated with HER2 low compared to HER2- or HER2+ tumors. Male breast cancer is rare, and little has been documented about prognosis, outcomes, and demographics. Do breast satisfaction and sexual well-being play a role in choosing between lumpectomy or mastectomy? The prognosis was worse for Black and young women with MBC, as seen in studies of women with early breast cancer. HER2-low status was associated with better OS and longer time-to-distant recurrence in a single-institution study.